Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Interim Trading Statement

19 Jul 2012 07:00

RNS Number : 9983H
Biome Technologies PLC
19 July 2012
 



19 July 2012

 

Biome Technologies plc ("Biome", "the Company" or "the Group")

 

Interim Trading Statement

 

 

Biome Technologies plc, the bioplastics and RF technology business, is pleased to announce a trading update, ahead of its Interim Results for the six-month period ended 30 June 2012, which are expected to be announced on 3 September 2012.

 

Total Group revenues achieved in the first half of 2012 were ÂŁ7.5m, down 28% on the same period in 2011. In the Trading Update of 31 May, it was stated that sales within the Bioplastics Division for April and May were markedly below our expectations following legislative changes in Italy and wider disruption to the supply and demand balance in Europe. This is reflected in the second quarter, with Group revenues of ÂŁ2.9m (Q2 2011: ÂŁ4.9m), 38% below the revenues of ÂŁ4.6m achieved in the first quarter.

 

The Bioplastics Division saw revenues drop from ÂŁ4.3m in Q1 to ÂŁ2.2m in the second quarter (Q2 2011: ÂŁ3.9m). Within this, Biotec was most adversely affected with revenues down 58% from ÂŁ3.0m in Q1 to ÂŁ1.2m in the second quarter (Q2 2011: ÂŁ1.8m) as third-party sales were depressed due to the previously reported demand changes in southern Europe. In Biome Bioplastics, revenues were down a more modest 26% to ÂŁ1.0m in the second quarter compared to ÂŁ1.3m in Q1 (Q2 2011: ÂŁ2.2m) with some evidence that the broader application base and geographic diversity is providing greater resilience to the current turbulence in the market.

 

The Stanelco RF Technologies Division continues to perform as expected with revenues of ÂŁ0.7m in Q2, up 95% compared to the first quarter (Q2 2011: ÂŁ0.9m). The pipeline for fibre optic furnace systems and associated spares continues to grow; orders for nine units to the value of ÂŁ1.2m have been received and are under build for the second half, with further orders pending. Diversification into new industrial markets continues and the Durapipe UK project is progressing well with the first prototype unit expected to be delivered shortly.

 

The Group's cash position at 30 June 2012 was £1.1m (30 April 2012: £1.5m). Following the period end, the Group announced that Biotec had entered into a €1.5m loan agreement with Sparkasse Emmerich and that €255k in repayment and interest had been repaid to Biome under the shareholder agreement. The Group's secured debt facility of up to £2m with Fortis Commercial Finance remains available but is currently not utilised.

 

The Board continues to believe that these market developments constitute a pause in a fast developing market and that the drivers of requirements for biodegradable and bio-based materials will grow with time.

 

With respect to the patent litigation, updated on 12 July, the recent positive findings in the Court of Turin in the context of other court findings provide further confidence in the value and potential of the Group's technology Biome is well placed and continues to expedite new product development with a focus on those opportunities likely to yield growth in the shorter term. Actions to reduce costs by around by ÂŁ0.6m on an annualised basis have now been completed and the benefits will build in the second half. The Group is trading in-line with the Board's revised expectations.

 

-Ends-

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com Tel: +44 (0) 2380 867 100

 

Daniel Stewart & Company plc

David Hart/Jamie Barklem

www.danielstewart.co.uk Tel: +44 (0) 20 7776 6550

 

First Columbus

Chris Crawford/Kelly Gardiner

www.first-columbus.com Tel: +44 (0) 20 3002 2070

 

FTI Consulting

Oliver Winters/Latika Shah Tel: +44 (0) 20 7831 3113

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFWFWAFESEEW
Date   Source Headline
11th Apr 20057:00 amRNSRe Agreement
7th Apr 20057:00 amRNSRe Agreement
6th Apr 200512:41 pmRNSAdditional Listing
24th Mar 20057:00 amRNSRe Contract
22nd Mar 20054:49 pmRNSAnnual Report and Accounts
21st Mar 20057:02 amRNSStatement on High Court
1st Mar 20057:01 amRNSUpdate re. trials with Asda
28th Feb 20057:00 amRNSFinal Results
23rd Feb 20054:45 pmRNSAdditional Listing
9th Feb 20053:16 pmRNSAgreement and Placing
8th Feb 20057:00 amRNSUpdate re. trials with Asda
31st Jan 20059:09 amRNSRe. Agreement
25th Jan 20057:00 amRNSDirectorate Change
17th Jan 200511:44 amRNSAdditional Listing
4th Jan 200511:06 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.